Octanoate-reduced Human Albumin
AssigneeCSL Behring GmbH
InventorsPeter Kiessling, Dietrich BOSSE, Johanness Zeiss, Gaston DIDERRICH
Life of this patent
Estimating the term…
Abstract
A method is described that improves the transport properties of albumin produced on an industrial scale, wherein the albumin is mixed, during the production process, with substances that saturate the binding points on the albumin. Furthermore, pasteurized and then octanoate-reduced human albumin and therapeutic uses of such albumin is described. Such albumin may be useful in detoxifying human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis.
Claims30
-12. (canceled)
A method for detoxifying human plasma, comprising administering or providing extracorporeally to a patient in need thereof an effective amount of a pasteurized albumin preparation, wherein, during production of the albumin preparation, one or more substances blocking binding sites of albumin are added before pasteurization and more than 50% of the one or more substances blocking binding sites are removed after pasteurization;
- and wherein aggregation stabilizers are not added to the albumin preparation after pasteurization.
A method for detoxifying human plasma, comprising administering or providing extracorporeally to a patient in need thereof an effective amount of a pasteurized albumin preparation, wherein the albumin preparation is essentially free of octanoate and N-acetyl-tryptophan.
Dependencies are inferred from the claim text.